What is Pacegenix?
Pacegenix is a biotechnology firm dedicated to pioneering precision cardiology. The company leverages advanced drug discovery techniques to develop mechanism-based therapies targeting cardiovascular and cardiac rhythm disorders. Its focus on next-generation cardiovascular therapeutics and early-stage biomedical innovation aims to significantly enhance patient treatment outcomes.
How much funding has Pacegenix raised?
Pacegenix has raised a total of $22.5M across 1 funding round:
Private Equity
$22.5M
Private Equity (2026): $22.5M, investors not publicly disclosed
What's next for Pacegenix?
The substantial enterprise-level funding Pacegenix has attracted indicates a strong market confidence in its innovative approach to cardiovascular disease. This capital infusion is expected to accelerate the development and commercialization of its pipeline therapies, positioning the company for significant growth and impact in the precision cardiology sector. Further strategic investments may follow as the company progresses through clinical stages and expands its market reach.
See full Pacegenix company page
